Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations.
Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. Caglevic C, et al. Among authors: mountzios g. JCO Glob Oncol. 2022 Aug;8:e2200123. doi: 10.1200/GO.22.00123. JCO Glob Oncol. 2022. PMID: 35994695 Free PMC article. Review.
Atezolizumab Treatment of Nonsquamous NSCLC.
Mountzios G, Calles A, Addeo A. Mountzios G, et al. N Engl J Med. 2018 Sep 20;379(12):1187. doi: 10.1056/NEJMc1809195. N Engl J Med. 2018. PMID: 30260156 No abstract available.
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.
Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B. Mountzios G, et al. Ann Oncol. 2019 Nov 1;30(11):1686-1688. doi: 10.1093/annonc/mdz295. Ann Oncol. 2019. PMID: 31504132 Free article. No abstract available.
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V; TERAVOLT study group. Whisenant JG, et al. Among authors: mountzios g. J Thorac Oncol. 2022 May;17(5):661-674. doi: 10.1016/j.jtho.2021.12.015. Epub 2022 Feb 1. J Thorac Oncol. 2022. PMID: 35121086 Free PMC article.
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J; TERAVOLT study group. Bestvina CM, et al. Among authors: mountzios g. JTO Clin Res Rep. 2022 Aug;3(8):100335. doi: 10.1016/j.jtocrr.2022.100335. Epub 2022 May 20. JTO Clin Res Rep. 2022. PMID: 35619644 Free PMC article.
First-line immunotherapy in non-small cell lung cancer: how to select and where to go.
Mogavero A, Cantale O, Mollica V, Anpalakhan S, Addeo A, Mountzios G, Friedlaender A, Kanesvaran R, Novello S, Banna GL. Mogavero A, et al. Among authors: mountzios g. Expert Rev Respir Med. 2023 Dec;17(12):1191-1206. doi: 10.1080/17476348.2024.2302356. Epub 2024 Feb 9. Expert Rev Respir Med. 2023. PMID: 38294292 Review.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Friedlaender A, et al. Among authors: mountzios g. Acta Oncol. 2020 Sep;59(9):1058-1063. doi: 10.1080/0284186X.2020.1781249. Epub 2020 Jun 17. Acta Oncol. 2020. PMID: 32762415
128 results